Update on Antimicrobial Resistance and the COVID-19 Pandemic

Update on Antimicrobial Resistance and the COVID-19 Pandemic

Early in the COVID-19 pandemic, concern was raised about potential inappropriate use of antimicrobials and whether this would impact efforts against antimicrobial resistance (AMR) and antimicrobial stewardship programs (ASP) during the crisis. In this article, we will review the status of AMR pre-pandemic, changes during the pandemic, and current developments.

Pre-pandemic

In one review of bacterial AMR, estimated global deaths in 2019 for 23 pathogens reached 4.95 million, with 1.27 million of these directly attributed to AMR.1Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399(10325):629-55. doi: 10.1016/S0140-6736(21)02724-0. Estimated attributable and associated disability-adjusted life-years (DALYs) were 47.9 million and 192 million, respectively. In the US, more than 3.1 million infections associated with bacterial and fungal AMR occurred in 2019, and 35,900 deaths in hospitalized patients.2CDC. Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Globally, six bacterial pathogens were responsible for a majority of deaths related to drug-resistant bacterial infections.1Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399(10325):629-55. doi: 10.1016/S0140-6736(21)02724-0. In the US, drug-resistant Streptococcus pneumoniae, Neisseria gonorrhoeae, Campylobacter, methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff) caused the most infections in hospitalized patients.2CDC. Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. (Figure 1)

Numbers alone underestimate the scope of the problem. An increasing number of microorganisms are multi-drug resistant, including Klebsiella pneumoniae, Mycobacterium tuberculosis, MRSA, vancomycin-resistant Enterococcus (VRE), C. diff, extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae, carbapenem-resistant acinetobacter species, Pseudomonas aeruginosa, Neisseria gonorrhoeae and Candida auris.2CDC. Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.^,3van Duin D, Paterson DL. Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. Infect Dis Clin North Am 2016;30(2):377-90. doi: 10.1016/j.idc.2016.02.004. Sixteen microorganisms are now classified as urgent or serious threats, including other drug-resistant microorganisms in addition to those described above.2CDC. Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

Antibiotic use in patients with COVID-19

Antibiotic use soared in hospital settings during the pandemic. In a prospective multicenter study across 260 hospitals in Great Britain on antibiotic use between early February and early June, 2020, 85% of hospitalized patients (almost 49,000) with confirmed/suspected COVID-19 were prescribed antimicrobials during admission.4Russell CD, Fairfield CJ, Drake TM et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021;2(8):e354-65. doi: 10.1016/S2666-5247(21)00090-2. In a retrospective review of US electronic health data for almost 5000 hospitalized patients it was found that more than half received antibiotics, 86% of them immediately and 96% within 48 hours (i.e., before confirmation of any bacterial co-infection).5PEW. Could Efforts to Fight the Coronavirus Lead to Overuse of Antibiotics? Study shows more than half of hospitalized COVID-19 patients in U.S. received antibiotics in pandemic’s first six months. March 10, 2021. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/03/could-efforts-to-fight-the-coronavirus-lead-to-overuse-of-antibiotics. Community-acquired bacterial pulmonary co-infection was later confirmed for 19% of patients (and urinary tract infections for 9% of patients). In a retrospective case study in New York, among the first 1,000 patients with COVID-19, 94.9% received antibiotics.6Argenziano MG, Bruce SL, Slater CL et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. Br Med J 2020;369:m1996. https://doi.org/10.1136/bmj.m1996.

Data from the SEMI-COVID19 Registry entered between March 1 and May 23, 2020, showed that 87.8% of 13,736 hospitalized patients received antibiotics.7Bendala Estrada AD, Calderón Parra J, Fernández Carracedo E et al. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infect Dis 2021;21:1144. https://doi.org/10.1186/s12879-021-06821-1. Among these patients, bacterial pneumonia was reported for 10.8%. In a subsequent report (end date June 23, 2020), 78.4% of patients had received antibiotics, while 10% had pulmonary bacterial coinfection (and 2% non-pulmonary coinfection).8Caldero´n-Parra J, Muiño-Miguez A, Bendala-Estrada AD et al. Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. PLoS ONE 2021;16(5): e0251340. https://doi.org/10.1371/journal.pone.0251340. A meta-analysis of 24 studies yielded confirmed bacterial infection in 8.4% of patients while almost 72% received antibiotics.9Langford BJ, So M, Raybardhan S et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020. https://doi.org/10.1016/j.cmi.2020.07.016. In December 2020, 9 studies on patients with COVID-19 were included in a review of bacterial/fungal coinfection in patients with infections caused by coronaviruses.10Rawson TM, Moore LSP, Zhu N et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020;71(9):2459-68. doi: 10.1093/cid/ciaa530. Among patients with COVID-19, 72% had received antimicrobial therapy, while 8% had a coinfection.

Similar patterns were found in other studies. In a multicenter multi-country European study, 85% of patients received antibiotics when admitted to intensive care units, while bacterial co-infection was found in 14%.11Conway Morris A, Kohler K et al. Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set. Crit Care 2022;26(1):236. doi: 10.1186/s13054-022-04108-8. In a study in the Philippines conducted March through August 2020, 55.1% of patients received antibiotics while 5.9% presented with co-infection.12Abad CL, Sandejas JCM, Poblete JB et al. Bacterial coinfection and antimicrobial use among patients with COVID-19 infection in a referral center in the Philippines: A retrospective cohort study. IJID Reg 2022;4:123-30. doi: 10.1016/j.ijregi.2022.07.003. In a review of patients admitted in Pakistan (up to the last peak in January 2022), 89.7% of patients received antibiotics.13Ramzan K, Shafiq S, Raees I et al. Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications. Antibiotics (Basel) 2022;11(6):789. doi: 10.3390/antibiotics11060789. Bacterial co-infections and secondary infections were found in just 1.14% and 3.14%, respectively. (Figure 2) Furthermore, a retrospective review of hospitalized patients with COVID-19 in two London hospitals revealed low levels of bacterial coinfection with rates comparable to a control group with influenza in the prior year.14Hughes S, Troise O, Donaldson H et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020;26(10):1395-9. doi: 10.1016/j.cmi.2020.06.025. Due to insufficient data, it has not been possible to determine rates of prescribing of anti-fungals.

Antibiotic prescribing in the dental setting

Antibiotic prescribing in the dental setting generally increased after onset of the pandemic, driven by practice closures and constraints. In England, antibiotic prescriptions were 25% higher overall for April through June 2020 compared to the same period in 2019.15Shah S, Wordley V, Thompson W. How did COVID-19 impact on dental antibiotic prescribing across England? Br Dent J 2020;229:601-4. https://doi.org/10.1038/s41415-020-2336-6. In Scotland, antibiotic prescriptions were 49% higher after dental care was halted and still 28% higher compared to pre-pandemic after care resumed.16Duncan EM, Goulao B, Clarkson J et al. ‘You had to do something’: prescribing antibiotics in Scotland during the COVID-19 pandemic restrictions and remobilisation. Br Dent J 2021:1-6. doi: 10.1038/s41415-021-3621-8. In public health dental clinics in Alberta, Canada, 76% more antibiotic prescriptions were provided from mid-March through the end of 2020 compared to 2019.17Rabie H, Figueiredo R. Provision of dental care by public health dental clinics during the COVID-19 pandemic in Alberta, Canada. Prim Dent J 2021;10(3):47-54. doi: 10.1177/20501684211029423. Increases were highest for April and May when dental offices were restricted. In Australia, antibiotic prescriptions initially decreased by 18% in April 2020, compared to the same period in 2019.18Mian M, Teoh L, Hopcraft M. Trends in Dental Medication Prescribing in Australia during the COVID-19 Pandemic. JDR Clin Trans Res 2021;6(2):145-52. doi: 10.1177/2380084420986766. In June 2020, a 20% increase in amoxicillin prescriptions was found compared to June 2019. In France, antibiotic prescriptions increased by 17.9% for dentists in 2020 compared to 2019.19Bara W, Brun-Buisson C, Coignard B, Watier L. Outpatient Antibiotic Prescriptions in France: Patients and Providers Characteristics and Impact of the COVID-19 Pandemic. Antibiotics (Basel) 2022;11(5):643. doi: 10.3390/antibiotics11050643. In contrast, they decreased by 30.4% and 17.0% for pediatricians and general practitioners, respectively.

Increases in the dental setting do not include antibiotic prescriptions written in outpatient emergency settings for dental infections when dental clinics were closed or curtailed.

Have changes in levels of antimicrobial resistance occurred?

In short, yes. A rapid increase for several multi-drug resistant microorganisms has occurred, most of which fall under the CDC list of ‘Urgent and Serious Threats’.20Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 2021;57(4):106324. doi: 10.1016/j.ijantimicag.2021.106324.^,21CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. https://www.cdc.gov/drugresistance/covid19.html. They include carbapenem-resistant New Delhi metallo-β-lactamase-producing Enterobacterales, ESBL-producing Klebsiella pneumoniae, Acinetobacter baumannii, MRSA and two fungi, including multi-triazole-resistant Aspergillus fumigatus.20Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 2021;57(4):106324. doi: 10.1016/j.ijantimicag.2021.106324. In the US, increases in hospital-acquired infections have ranged from 13% to 78% for 8 drug-resistant microorganisms.21CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. https://www.cdc.gov/drugresistance/covid19.html. (Figure 3)

Challenges during COVID-19

As we know, dental offices closed shortly after the pandemic began and once re-opened triaging of patients became standard practice. Depending on location, dentists were instructed to manage patients remotely and use antibiotics where appropriate and similar guidance was provided based on location for deferred dental emergencies.15Shah S, Wordley V, Thompson W. How did COVID-19 impact on dental antibiotic prescribing across England? Br Dent J 2020;229:601-4. https://doi.org/10.1038/s41415-020-2336-6.^,22Luzzi V, Ierardo G, Bossù M, Polimeni A. COVID-19: Pediatric Oral Health during and after the Pandemics. Appl. Sci 2020;10:1-8. doi: 10.20944/preprints202004.0002.v1. Dentists were concerned that antibiotic use would now increase when they had intended to do the opposite before the pandemic occurred.16Duncan EM, Goulao B, Clarkson J et al. ‘You had to do something’: prescribing antibiotics in Scotland during the COVID-19 pandemic restrictions and remobilisation. Br Dent J 2021:1-6. doi: 10.1038/s41415-021-3621-8. Prior to the pandemic progress was made on antibiotic stewardship. In one example, a successful ASP within academic dental clinics resulted in a 72.9% reduction in antibiotic prescribing.23Gross AE, Hanna D, Rowan SA et al. Successful Implementation of an Antibiotic Stewardship Program in an Academic Dental Practice. Open Forum Inf Dis 2019;6(3):ofz067. https://doi.org/10.1093/ofid/ofz067.

In hospital settings, antimicrobials were frequently prescribed against a background of crisis and uncertainty amid sparse knowledge on COVID-19, an absence of effective therapies and lack of treatment guidelines.7Bendala Estrada AD, Calderón Parra J, Fernández Carracedo E et al. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infect Dis 2021;21:1144. https://doi.org/10.1186/s12879-021-06821-1.^,24Peghin M, Vena A, Graziano E et al. Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. Ther Adv Inf Dis January 2022. doi:10.1177/20499361221095732. A further factor may have been the recommendation that antibiotic therapy be initiated for patients with community-acquired pneumonia since at disease onset no definitive test exists to inform whether a case is viral/bacterial.7Bendala Estrada AD, Calderón Parra J, Fernández Carracedo E et al. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infect Dis 2021;21:1144. https://doi.org/10.1186/s12879-021-06821-1.^,25Metlay JP, Waterer GW, Long AC et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200(7):e45-67. https://doi.org/10.1164/rccm.201908-1581ST. Adherence to ASP decreased. For example, results for an Italian survey conducted in July 2021 in infectious disease hospital units revealed that half of ASP were reduced, and 7 of 9 had ceased.26Comelli A, Genovese C, Lombardi A et al. What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres. Antimicrob Resist Infect Control 2022;11(1):108. doi: 10.1186/s13756-022-01152-5. ASP did restart in units where this was a priority. Regionally, programs were widely discontinued.

However, ASP that rapidly modified protocols during the pandemic could reduce the use and duration of antibiotic therapies.24Peghin M, Vena A, Graziano E et al. Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. Ther Adv Inf Dis January 2022. doi:10.1177/20499361221095732. In a Scottish study conducted shortly after national antibiotic recommendations for suspected bacterial respiratory tract infection complicating COVID-19 were introduced, antibiotic prescribing rates for a single day (over a period of 10 days) were compared for patients with and without COVID-19 in critical and non-critical care hospital units in April 2020.27Seaton RA, Gibbons CL, Cooper L et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect 2020;81(6):952-60. doi: 10.1016/j.jinf.2020.09.024. Antibiotic prescribing for patients with COVID-19 was relatively low, and in non-critical care units a high proportion were narrow spectrum antibiotics, with broad-spectrum antibiotics spared. Broad spectrum antibiotics were, however, prescribed proportionately more in critical care settings.27Seaton RA, Gibbons CL, Cooper L et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect 2020;81(6):952-60. doi: 10.1016/j.jinf.2020.09.024. In the US, current difficulties include the lack of data available currently on numerous threatening drug-resistant microorganisms for 2020, due to resource constraints and other limitations.21CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. https://www.cdc.gov/drugresistance/covid19.html.

Pipeline Developments

Current research approaches for antimicrobials include novel methods that affect the microorganisms without killing them and compounds that interfere with bacterial metabolic processes.28Robins-Browne R. Disarming Bacterial Virulence. Biology, Health and Medicine. Aug 23, 2017. https://www.scientia.global/professor-roy-robins-browne-disarming-bacterial-virulence/. For example, research on anti-adhesive molecules that could combat adhesive proteins on the surface of pili/fimbrae that foster bacterial adhesion to the bladder wall for some E. coli strains.29Ribić R, Meštrović T, Neuberg M, Kozina G. Effective anti-adhesives of uropathogenic Escherichia coli. Acta Pharmaceutica 2018;68(1):1-18. https://doi.org/10.2478/acph-2018-0004. FabI inhibitors target an enzymatic catalyst involved in bacterial fatty acid production. ‘Fabimycin’ tackles drug-resistant gram-negative bacteria, and in mice has effectively reduced the level of drug-resistant K. pneumoniae.30Parker EN, Cain BN, Hajian B et al. An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections. ACS Cent Sci 2022;8(8):1145-58. https://doi.org/10.1021/acscentsci.2c00598. Teixobactin is produced by soil-dwelling bacteria and kills other bacteria present. In vitro, synthetic teixobactins can kill a wide range of microorganisms and in mice shown to eliminate MRSA.31University of Liverpool. Liverpool scientists develop synthetic antibiotics that could save millions of lives. March 29, 2022. https://www.liverpool.ac.uk/health-and-life-sciences/news-and-events/articles/liverpool-scientists-develop-synthetic-antibiotics-that-could-save-millions-of-lives/. A ‘jumbo phage’ has also been developed that produces an outer protective single-protein coating once it enters the bacterial host, creating a barrier against bacterial attack while the jumbo phage can still release its genetic material.32Laughlin TG, Deep A, Prichard AM et al. Architecture and self-assembly of the jumbo bacteriophage nuclear shell. Nature 2022;608:429-35. https://doi.org/10.1038/s41586-022-05013-4. Closer to home, in newly-published research, a second-generation antimicrobial peptide (DGL13K) derived from a salivary protein has been found in vitro to offer antimicrobial efficacy against several drug-resistant and other bacteria.33Gorr S-U, Brigman HV, Anderson JC, Hirsch EB. The antimicrobial peptide DGL13K is active against drug-resistant gram-negative bacteria and sub-inhibitory concentrations stimulate bacterial growth without causing resistance. PLoS ONE 2022;17(8): e0273504. https://doi.org/10.1371/journal.pone.0273504.

Conclusions

While ASP were gaining ground and reductions in prescribing of antimicrobials were being achieved, COVID-19 resulted in increased prescribing and increased AMR and drug-resistant infections. Appropriately adapted ASP have been shown to work. In addition, electronic health records and e-prescribing offer opportunities to better track prior prescriptions and make more informed decisions. There is also promising research on innovative antimicrobials, however, this takes a significant investment. It also takes considerable time, many drug candidates do not come to fruition, and the stock of effective antimicrobials is dwindling. In the meantime, more attention to tracking AMR, further integration of ASP, resources for antimicrobial drug development, vaccinations, increased infection prevention efforts and new technologies are needed to contain threats and prevent drug-resistant outbreaks.

References

• 1.American Association of Pediatric Dentistry. Policy on Early Childhood Caries (ECC): Classifications, Consequences, and Preventive Strategies. 2016. https://www.aapd.org/media/policies_guidelines/p_eccclassifications.pdf.
• 2.Fleming E, Afful J. Prevalence of Total and Untreated Dental Caries Among Youth: United States, 2015-2016. NCHS Data Brief 2018;(307):1-8.
• 3.Chen J, Duangthip D, Gao SS et al. Oral Health Policies to Tackle the Burden of Early Childhood Caries: A Review of 14 Countries/Regions. Front Oral Health 2021;2:670154. doi: 10.3389/froh.2021.670154.
• 4.Zhang M, Zhang X, Zhang Y et al. Assessment of risk factors for early childhood caries at different ages in Shandong, China and reflections on oral health education: a cross-sectional study. BMC Oral Health 2020;20(1):139. doi: 10.1186/s12903-020-01104-8.
• 5.Srisilapanan P, Nirunsittirat A, Roseman J. Trends over Time in Dental Caries status in Urban and Rural Thai Children. J Clin Exp Dent 2017;9(10):e1201-06. doi: 10.4317/jced.54054.
• 6.Castillo JL, Palma C, Cabrera-Matta A. Early Childhood Caries in Peru. Front Public Health. 2019;7:337. https://doi.org/10.3389/fpubh.2019.00337.
• 7.Gao XL, Hsu CY, Loh T et al. Dental caries prevalence and distribution among preschoolers in Singapore. Community Dent Health 2009;26(1):12-7.
• 8.Pierce A, Singh S, Lee J et al. The Burden of Early Childhood Caries in Canadian Children and Associated Risk Factors. Front Public Health 2019;7:328. doi: 10.3389/fpubh.2019.00328.
• 9.Petersen PE, Bourgeois D, Ogawa H et al. The global burden of oral diseases and risks to oral health. Bull World Health Org 2005;83(9):661-9.
• 10.Alkhtib AO, Mohamed HG. Current knowledge about early childhood caries in the gulf cooperation council with worldwide reflection: Scoping review of the scientific literature (2010–2021). PLOS Glob Public Health 2023;3(1): e0001228. https://doi.org/10.1371/journal.pgph.0001228.
• 11.Tinanoff N, Baez RJ, Diaz Guillory C et al. Early childhood caries epidemiology, aetiology, risk assessment, societal burden, management, education, and policy: global perspective. Int J Paediatr Dent 2019;29:238-48.
• 12.Meyer F, Enax J. Early Childhood Caries: Epidemiology, Aetiology, and Prevention. Int J Dent 2018:1415873. doi: 10.1155/2018/1415873.
• 13.Abanto J, Carvalho TS, Mendes FM et al. Impact of oral diseases and disorders on oral health-related quality of life of preschool children. Commun Dent Oral Epidemiol 2011;39(2):105-14.
• 14.Shokravi M, Khani-Varzgan F, Asghari-Jafarabadi M et al. The Impact of Child Dental Caries and the Associated Factors on Child and Family Quality of Life. Int J Dent 2023;2023:4335796. doi: 10.1155/2023/4335796.
• 15.Díaz S, Mondol M, Peñate A et al. Parental perceptions of impact of oral disorders on Colombian preschoolers’ oral health-related quality of life. Acta Odontol Latinoam 2018;31(1):23-31.
• 16.Corrêa-Faria P, Silva KC, Costa LR. Impact of dental caries on oral health-related quality of life in children with dental behavior management problems. Braz Oral Res 2022;36:e041. doi: 10.1590/1807-3107bor-2022.vol36.0041.
• 17.Barbosa TDS, Gavião MBD. Evaluation of the family impact scale for use in Brazil. J Appl Oral Sci 2009;17(5):397-403.
• 18.Pakkhesald M, Riyahi E, Alhosseini AAN, Amdjadi P. Impact of dental caries on oral health related quality of life among preschool children: perceptions of parents. BMC Oral Health 2021;21:68. https://doi.org/10.1186/s12903-021-01396-4.
• 19.Scarpelli AC, Oliveira BH, Tesch FC et al. Psychometric properties of the Brazilian version of the early childhood oral health impact scale (B-ECOHIS). BMC Oral Health 2011;11(1):19.
• 20.Petersen PE. The World Oral Health Report 2003: continuous improvement of oral health in the 21st century—the approach of the WHO Global Oral Health Programme. Commun Dent Oral Epidemiol 2003;31:3-24.
• 21.American Academy of Pediatric Dentistry. Policy. The State of Little Teeth. https://www.aapd.org/assets/1/7/State_of_Little_Teeth_Final.pdf.
• 22.BaniHani A, Deery C, Toumba J et al. The impact of dental caries and its treatment by conventional or biological approaches on the oral health-related quality of life of children and carers. Int J Paediatr Dent 2018;28(2):266-76. doi: 10.1111/ipd.12350.
• 23.Alkarimi H A, Watt R G, Pikhart H et al. Impact of treating dental caries on schoolchildren’s anthropometric dental, satisfaction and appetite outcomes: a randomized clinical trial. BMC Public Health 2012;12:706-14.
• 24.Chrisopoulos S, Harford JE. Oral Health and Dental Care in Australia: Key Facts and Figures 2015, Australian Institute of Health and Welfare and the University of Adelaide, Canberra, ACT, Australia, 2016.
• 25.Ramos-Gomez FJ, Weintraub JA, Gansky SA et al. Bacterial, behavioral and environmental factors associated with early childhood caries. J Clin Pediatr Dent 2002;26(2):165-73. doi: 10.17796/jcpd.26.2.t6601j3618675326.
• 26.Kawashita Y, Kitamura M, Saito T. Early childhood caries. Int J Dent 2011;2011:725320. doi: 10.1155/2011/725320.
• 27.Martínez AR, Ruiz-Guillén A, Romero-Maroto M et al. Impact of Breastfeeding and Cosleeping on Early Childhood Caries: A Cross-Sectional Study. J Clin Med 2021;10:1561. https://doi.org/10.3390/jcm10081561.
• 28.Alade M, Folayan MO, El Tantawi M et al. Early childhood caries: Are maternal psychosocial factors, decision-making ability, and caries status risk indicators for children in a sub-urban Nigerian population? BMC Oral Health 2021;21:73. https://doi.org/10.1186/s12903-020-01324-y.
• 29.Avila WM, Pordeus IA, Paiva SM, Martins CC. Breast and Bottle Feeding as Risk Factors for Dental Caries: A Systematic Review and MetaAnalysis. PLoS ONE 2015;10(11): e0142922. doi:10.1371/journal.pone.0142922.
• 30.Peres KG, Nascimento GG, Peres MA et al. Impact of prolonged breastfeeding on dental caries: A population-based birth cohort study. Pediatrics 2017;140:e20162943.
• 31.Perera PJ, Fernando MP, Warnakulasooriya TD, Ranathunga N. Effect of feeding practices on dental caries among preschool children: a hospital based analytical cross sectional study. Asia Pac J Clin Nutr 2014;23(2):272-7. doi: 10.6133/apjcn.2014.23.2.13.
• 32.Iida H, Auinger P, Billings RJ, Weitzman M. Association between infant breastfeeding and early childhood caries in the United States. Pediatrics 2007;120: e944-52.
• 33.Nirunsittirat A, Pitiphat W, McKinney CM et al. Breastfeeding Duration and Childhood Caries: A Cohort Study. Caries Res 2016;50(5):498-507. https://doi.org/10.1159/000448145.
• 34.Lapps Wert KM, Lindemeyer R, Spatz DL. Breastfeeding, co-sleeping and dental health advice. MCN Am J Matern Child Nurs 2015;40:174-9.
• 35.Clark MB, Slayton RL, AAP Section on Oral Health. Fluoride Use in Caries Prevention in the Primary Care Setting. Pediatrics 2020;146(6):e2020034637.
• 36.Public Health England. Guidance Breastfeeding and dental health. Updated 30 January 2019. https://www.gov.uk/government/publications/breastfeeding-and-dental-health/breastfeeding-and-dental-health.
• 37.Guidance. Delivering better oral health: an evidence-based toolkit for prevention. https://www.gov.uk/government/publications/delivering-better-oral-health-an-evidence-based-toolkit-for-prevention.
• 38.Lee JY, Bouwens TJ, Savage MF, Vann WF Jr. Examining the cost effectiveness of early dental visits. Pediatr Dent 2006;28(2):102-5, discussion 192-8.
• 39.U.S. Public Health Service Recommendation for Fluoride Concentration in Drinking Water for the Prevention of Dental Caries. Public Health Rep 2015;130(4):318-31.
• 40.American Association of Pediatric Dentistry. Caries-risk Assessment and Management for Infants, Children, and Adolescents. Latest revision, 2019. https://www.aapd.org/media/Policies_Guidelines/BP_CariesRiskAssessment.pdf.
• 41.Weyant RJ, Tracy SL, Anselmo T et al. Topical fluoride for caries prevention: Executive summary of the updated clinical recommendations and supporting systematic review. J Am Dent Assoc 2013;144(11):1279-91. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581720/.
• 42.American Association of Pediatric Dentistry. Fluoride therapy, revised 2023. https://www.aapd.org/globalassets/media/policies_guidelines/bp_fluoridetherapy.pdf
• 43.American Association of Pediatric Dentistry. Oral Health Policies & Recommendations (The Reference Manual of Pediatric Dentistry). Use of Pit-and-Fissure Sealants (2016). https://www.aapd.org/research/oral-health-policies–recommendations/pit_and_fissure_sealants/.
• 44.Ferreira Zandona AG, Ritter AV, Eidson RS. Dental caries: Etiology, caries risk assessment, and management. Ch2, p43. In: Ritter AV, Boushell LW, Walter R. Sturdevant’s art & science of operative dentistry-e-book. 7th Ed. Elsevier Health Sciences, 2017.
• 45.Slayton RL, Urquhart O, Araujo MWB et al. Evidence-based clinical practice guideline on nonrestorative treatments for carious lesions: A report from the American Dental Association. J Am Dent Assoc 2018;149(10):837-49. e19. doi: 10.1016/j.adaj.2018.07.002. https://www.aapd.org/media/Policies_Guidelines/R_ChairsideGuide.pdf.
• 46.American Academy of Pediatric Dentistry. Policy on the use of silver diamine fluoride for pediatric dental patients. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2022:72-5. https://www.aapd.org/media/Policies_Guidelines/P_SilverDiamine.pdf.
• 47.American Association of Pediatric Dentistry. Guideline on Restorative Dentistry, 2016. https://www.aapd.org/assets/1/7/G_Restorative1.PDF.
• 48.Krol DM, Whelan K, AAP Section on Oral Health. Maintaining and Improving the Oral Health of Young Children. Pediatrics 2023;151(1):e2022060417.
• 49.American Academy of Pediatrics. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. www.aap.org/en-us/Documents/ oralhealth_RiskAssessmentTool.pdf.
• 50.Moyer VA, US Prevention Services Task Force. Prevention of dental caries in children from birth through age 5 years: US Preventive Services Task Force recommendation statement. Pediatrics 2014;133(6):1102-11.
• 51.Macpherson LM, Rodgers J, Conway DI. Childsmile after 10 years part 2: programme development, implementation and evaluation. Dental Update 2019; 46(3):238-46.